Cited 0 times in
Hepatitis B Prophylaxis after Liver Transplantation in Korea: Analysis of the KOTRY Database
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, GC | - |
dc.contributor.author | Hwang, S | - |
dc.contributor.author | Kim, MS | - |
dc.contributor.author | Jung, DH | - |
dc.contributor.author | Song, GW | - |
dc.contributor.author | Lee, KW | - |
dc.contributor.author | Kim, JM | - |
dc.contributor.author | Lee, JG | - |
dc.contributor.author | Ryu, JH | - |
dc.contributor.author | Choi, DL | - |
dc.contributor.author | Wang, HJ | - |
dc.contributor.author | Kim, BW | - |
dc.contributor.author | Kim, DS | - |
dc.contributor.author | Nah, YW | - |
dc.contributor.author | You, YK | - |
dc.contributor.author | Kang, KJ | - |
dc.contributor.author | Yu, HC | - |
dc.contributor.author | Park, YH | - |
dc.contributor.author | Lee, KJ | - |
dc.contributor.author | Kim, YK | - |
dc.date.accessioned | 2022-11-11T04:09:36Z | - |
dc.date.available | 2022-11-11T04:09:36Z | - |
dc.date.issued | 2020 | - |
dc.identifier.issn | 1011-8934 | - |
dc.identifier.uri | http://repository.ajou.ac.kr/handle/201003/22558 | - |
dc.description.abstract | BACKGROUND: Prophylaxis for hepatitis B virus (HBV) recurrence is essential after liver transplantation (LT) in HBV-associated recipients. We conducted real-world analysis of HBV prophylaxis after LT in the Korean population. METHODS: Korean Organ Transplantation Registry (KOTRY) database and additionally collected data (n = 326) were analyzed with special reference to types of HBV prophylaxis. RESULTS: The study cohort comprised 267 cases of living-donor LT and 59 cases of deceased-donor LT. Hepatocellular carcinoma (HCC) was diagnosed in 232 (71.2%) of these subjects. Antiviral agents were used in 255 patients (78.2%) prior to LT. HBV DNA was undetectable in 69 cases (21.2%) and detectable over wide concentrations in the other 257 patients (78.8%) prior to LT. Polymerase chain reaction analysis of the store blood samples detected HBV DNA in all patients, with 159 patients (48.9%) showing concentrations > 100 IU/mL. Post-transplant HBV regimens during the first year included combination therapy in 196 (60.1%), hepatitis B immunoglobulin (HBIG) monotherapy in 121 (37.1%), and antiviral monotherapy in 9 (2.8%). In the second post-transplant year, these regimens had changed to combination therapy in 187 (57.4%), HBIG monotherapy in 112 (34.4%), and antiviral monotherapy in 27 (8.3%). Trough antibody to hepatitis B surface antigen titers > 500 IU/mL and >1,000 IU/mL were observed in 61.7% and 25.2%, respectively. The mean simulative half-life of HBIG was 21.6 +/- 4.3 days with a median 17.7 days. Up to 2-year follow-up period, HCC recurrence and HBV recurrence developed in 18 (5.5%) and 6 (1.8%), respectively. HCC recurrence developed in 3 of 6 patients with HBV recurrence. CONCLUSION: Combination therapy is the mainstay of HBV prophylaxis protocols in a majority of Korean LT centers, but HBIG was often administered excessively. Individualized optimization of HBIG treatments using SHL is necessary to adjust the HBIG infusion interval. | - |
dc.language.iso | en | - |
dc.subject.MESH | Antiviral Agents | - |
dc.subject.MESH | Cohort Studies | - |
dc.subject.MESH | DNA, Viral | - |
dc.subject.MESH | Drug Therapy, Combination | - |
dc.subject.MESH | Hepatitis B Surface Antigens | - |
dc.subject.MESH | Hepatitis B virus | - |
dc.subject.MESH | Hepatitis B | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Immunoglobulins | - |
dc.subject.MESH | Liver Transplantation | - |
dc.subject.MESH | Living Donors | - |
dc.subject.MESH | Registries | - |
dc.subject.MESH | Republic of Korea | - |
dc.title | Hepatitis B Prophylaxis after Liver Transplantation in Korea: Analysis of the KOTRY Database | - |
dc.type | Article | - |
dc.identifier.pmid | 32056398 | - |
dc.identifier.url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7025905 | - |
dc.subject.keyword | Hepatitis B Virus | - |
dc.subject.keyword | Recurrence | - |
dc.subject.keyword | Liver Transplantation | - |
dc.subject.keyword | Hepatitis B Immunoglobulin | - |
dc.subject.keyword | Antiviral Agent | - |
dc.contributor.affiliatedAuthor | Kim, BW | - |
dc.type.local | Journal Papers | - |
dc.identifier.doi | 10.3346/jkms.2020.35.e36 | - |
dc.citation.title | Journal of Korean medical science | - |
dc.citation.volume | 35 | - |
dc.citation.number | 6 | - |
dc.citation.date | 2020 | - |
dc.citation.startPage | e36 | - |
dc.citation.endPage | e36 | - |
dc.identifier.bibliographicCitation | Journal of Korean medical science, 35(6). : e36-e36, 2020 | - |
dc.identifier.eissn | 1598-6357 | - |
dc.relation.journalid | J010118934 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.